ClinicalTrials.gg
Active, not recruitingNCT07340476Updated Mar 9, 2026

A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects

A Phase 1 interventional study of AK112 (New Site) and AK112 (Original Site) in Healthy Male Subjects, sponsored by Akeso. Active, not recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Akeso · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the pharmacokinetic (PK) similarity of AK112 (an anti-PD-1/VEGF bispecific antibody) from the proposed new manufacturing site and the approved original site in healthy male subjects.

Secondary objectives are to assess the safety, tolerability, and immunogenicity of AK112 from the proposed new manufacturing site and the approved original site.

02

Conditions studied

  • Healthy Male Subjects

Keywords

  • AK112
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signing form before the trial and having a full understanding of the trial content, process and possible adverse reactions;
  2. Able to complete the study according to the requirements of the study protocol.
  3. Males aged 18 to 45;
  4. (BMI) is 19.0\~26.0 kg/m2, and body weight is 55.0\~75.0kg ;

Exclusion criteria

Exclusion Criteria:

  1. Those with a history of hypertension or blood pressure abnormalities at screening considered by the investigator.
  2. Those with a history of proteinuria or the presence of clinically significant proteinuria at screening as judged by the investigator.
  3. Those with a history of severe bleeding tendency or coagulation dysfunction, or a history of thrombosis or hemorrhagic events; those with a history of esophageal-gastric varices, severe ulcers, gastrointestinal obstruction, or intra-abdominal abscess; those with a history of digestive tract perforation, hemorrhage, or fistula; those with a history of (TIA), cerebrovascular accident (stroke), hypertensive crisis, or hypertensive encephalopathy; those with a current unhealed wound or fracture.
  4. Those with a history of diseases (including personal or family history of hereditary immunodeficiency).
  5. Those with a history of malignant tumor.
  6. Those with a history of tuberculosis or clinical manifestations suspected to be tuberculosis (including but not limited to pulmonary tuberculosis, lymph node tuberculosis, tuberculous pleurisy, etc.).
  7. Those with a history of recurrent or chronic infections, including a history of chronic or recurrent infections such as: chronic kidney infection, chronic thoracic cavity infection (e.g., bronchiectasis), sinusitis, recurrent urinary tract infections, open, draining, or infected skin wounds.
  8. Those with a history of acute infection within 4 weeks prior to randomization; or those with a history of opportunistic infections (e.g., herpes zoster, active cytomegalovirus, Pneumocystis jirovecii, histoplasmosis, aspergillosis, mycobacterial infections, etc.) within 6 months prior to randomization.
  9. Those who underwent major surgery within 3 months prior to randomization or experienced serious trauma, or those who plan to undergo surgical procedures during the trial period.
  10. Those who donated blood or experienced significant blood loss (≥400 mL) within 3 months prior to randomization, received blood transfusion or blood products, or plan to donate blood or blood components during the trial period or within 3 months after completion of the trial.
  11. Those unable to tolerate venipuncture or with a history of fainting during blood draws or injections (vasovagal reaction).
  12. Those with a known allergy to any component of the product, or those with a history of allergy to two or more drugs, foods, or other substances.
  13. Those with a history of other diseases affecting the digestive, respiratory, cardiovascular, endocrine, urinary, neurological, hematologic, or metabolic systems that the investigator deems to have ongoing clinical significance.
  14. Those with a positive result in the urine drug screen test (for morphine, methamphetamine, ketamine, methylenedioxymethamphetamine [MDMA], tetrahydrocannabinol [THC]).
  15. Those with a positive alcohol breath test.
  16. Those who test positive for any of the following: (HIV) antibody, Virus (HCV) antibody, Syphilis test (RPR), Virus (HBV) surface antigen, e-antigen (HBeAg), or core antibody (HBcAb).
  17. Those with abnormal findings in other examinations (physical examination, vital signs, chest X-ray, laboratory tests, etc.) that are considered clinically significant by the investigator.
  18. Those who have previously used any drug targeting , PD-L1, VEGF, or VEGFR pathways.
  19. Those who received other investigational medicinal products or participated in another interventional clinical trial within 3 months prior to randomization.
  20. Those vaccinated with live or attenuated vaccines within 3 months prior to randomization, or those vaccinated with inactivated vaccines within 14 days prior to randomization, or those who plan to receive vaccinations during the trial period.
  21. Those who used any medication (including traditional Chinese medicine, health supplements, etc.) within 14 days prior to randomization, or those whose last dose was administered less than 5 half-lives before the randomization date, whichever is longer.
  22. Those with a history of drug abuse or those who used soft drugs (e.g., marijuana) or hard drugs (e.g., cocaine, phencyclidine, etc.) within 1 year prior to receiving the investigational product.
  23. Those who are smokers or smoked more than 5 cigarettes per day within 3 months prior to randomization, or those unable to abstain from all tobacco products during hospitalization.
  24. Those who are heavy drinkers or frequent drinkers within 12 months prior to randomization, defined as consuming more than 14 units of alcohol per week (1 unit = 360 mL beer or 45 mL spirits [40% alcohol] or 150 mL wine); or those unwilling to abstain from alcohol or any alcoholic beverages during the trial period.
  25. Those with special dietary requirements that prevent compliance with the standardized diet, or those who are lactose intolerant.
  26. Those whose subject or partner has plans for pregnancy during the study period through 3 months after trial completion, or those unwilling to use reliable measures (such as abstinence, sterilization, oral contraceptives, injectable contraceptives like medroxyprogesterone acetate, subdermal implants, condoms, etc.).
  27. Those who may be unable to complete this study for other reasons, or those unable to comply with the study procedures during the study period, or those deemed by the investigator to have other reasons making them unsuitable for participation in the trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    AK112 (New Site)

    AK112 (New Site) 3mg/kg, will be administrated intravenously in 60±10 minutes.

    Drug: AK112 (New Site)

  • Active comparator
    AK112 (Original Site)

    AK112 (Original Site) 3mg/kg, will be administrated intravenously in 60±10 minutes.

    Drug: AK112 (Original Site)

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC0-infinity)

    Time frame: From pre-dose to day 43

Secondary outcomes

  1. Area under the plasma concentration-time curve (AUC0-t)

    Time frame: From pre-dose to day 43

  2. Maximum plasma concentration (Cmax)

    Time frame: From pre-dose to day 43

  3. Volume of distribution (Vd)

    Time frame: From pre-dose to day 43

  4. Clearance (CL)

    Time frame: From pre-dose to day 43

  5. Ratio of AUC0-t/AUC0-infinity

    Time frame: From pre-dose to day 43

  6. Time to maximum concentration (Tmax)

    Time frame: From pre-dose to day 43

  7. Half-life (t1/2)

    Time frame: From pre-dose to day 43

  8. Incidence and severity of adverse events (AEs)

    Time frame: Up to day 43

  9. Number and percentage of subjects with detectable ADA

    Time frame: From pre-dose to day 43

07

Study locations

1 site
  • Zhejiang Xiaoshan Hospital
    Zhejiang, Xiaoshan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Apr 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 14, 2026
StartActual
Dec 11, 2025
Primary completionEst.
Apr 10, 2026
CompletionEst.
Jul 30, 2026
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07340476
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Dec 11, 2025
Primary completion
Apr 10, 2026 (estimated)
Completion
Jul 30, 2026 (estimated)
Last update
Mar 9, 2026

Study contacts

Jinliang Chen, MD
principal investigator · Zhejiang Xiaoshan hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion